Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for tough blood cancers

NCT ID NCT04068597

Recruiting now Disease control Sponsor: CellCentric Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated Jun 23, 2026 · Updated 23 times

Summary

This study tests a new oral drug called CCS1477 (inobrodib) in people with advanced blood cancers such as acute myeloid leukemia, non-Hodgkin lymphoma, multiple myeloma, and high-risk myelodysplastic syndrome. The drug is given alone or with other cancer medicines. The goal is to see if it is safe and can shrink or control the cancer. About 250 adults whose cancer has returned or not responded to prior treatments are being enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CIOCC Hospital Universitario HM Sanchinarro

    COMPLETED

    Madrid, 28050, Spain

  • Cancer and Haematology Centre

    RECRUITING

    Oxford, OX3 7LE, United Kingdom

    Contact

  • Community Health Network

    RECRUITING

    Indianapolis, Indiana, 46227, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Emory Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Gartnavel General Hospital

    RECRUITING

    Glasgow, G12 0YN, United Kingdom

    Contact

  • Gustave Roussy

    COMPLETED

    Villejuif, 94805, France

  • Hospital Clínic de Barcelona

    RECRUITING

    Barcelona, 08036, Spain

    Contact

  • Hospital Germans Trias i Pujol/ ICO Badalona

    RECRUITING

    Badalona, 08916, Spain

    Contact

  • Hospital Infanta Leonor

    RECRUITING

    Madrid, 28031, Spain

    Contact

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

    Contact

  • Hospital Universitario Gregorio Marañón

    RECRUITING

    Madrid, 28009, Spain

    Contact

  • Hospital Universitario Ramón y Cajal

    RECRUITING

    Madrid, 28034, Spain

    Contact

  • Hospital Universitario de La Princesa

    RECRUITING

    Madrid, 28006, Spain

    Contact

  • Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana

    RECRUITING

    Valencia, 46026, Spain

    Contact

  • ICO L'Hospitalet (Instituto Catalán de Oncología)

    RECRUITING

    Barcelona, 08908, Spain

    Contact

  • Imperial College

    RECRUITING

    London, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Institute Bergonie

    COMPLETED

    Bordeaux, 33076, France

  • Karolinska Comprehensive Cancer Center

    COMPLETED

    Stockholm, Sweden

  • Leicester Royal Infirmary

    RECRUITING

    Leicester, United Kingdom

    Contact

  • NIHR University College London Clinical Research Facility

    RECRUITING

    London, W1T 7HA, United Kingdom

    Contact

  • Nebraska Cancer Specialists

    RECRUITING

    Omaha, Nebraska, 68130, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Newcastle upon Tyne Hospitals

    RECRUITING

    Newcastle upon Tyne, United Kingdom

    Contact Email: •••••@•••••

  • Nottingham University Hospitals NHS Trust

    RECRUITING

    Nottingham, NG5 1PB, United Kingdom

    Contact

  • Penn Medicine - Abramson Cancer Center Perelman

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Royal Derby Hospital

    RECRUITING

    Derby, DE22 3NE, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Royal Stoke University Hospital

    RECRUITING

    Stoke-on-Trent, ST4 6QG, United Kingdom

    Contact

  • Sarah Cannon Research Institute UK

    RECRUITING

    London, W1G 6AD, United Kingdom

    Contact

  • St Bartholomew's Hospital

    RECRUITING

    London, EC1A 7BE, United Kingdom

    Contact

  • The Center for Cancer and Blood Disorders (CCBD)

    RECRUITING

    Bethesda, Maryland, 20817, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The Christie Hospital

    RECRUITING

    Manchester, United Kingdom

    Contact

  • The Clatterbridge Cancer Centre NHS Foundation Trust,

    RECRUITING

    Bebington, CH63 4JY, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The Royal Marsden

    RECRUITING

    Sutton, Surrey, SM2 5PT, United Kingdom

    Contact

  • Universidad de Navarra

    RECRUITING

    Pamplona, 31008, Spain

    Contact

  • University Hospital Vall D'Hebron

    COMPLETED

    Barcelona, 08035, Spain

  • University Hospital of Southampton

    RECRUITING

    Southampton, SO16 6YD, United Kingdom

    Contact

  • University Hospital of Wales

    RECRUITING

    Cardiff, United Kingdom

    Contact

  • University Hospitals Bristol

    RECRUITING

    Bristol, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Nebraska Medical Center

    RECRUITING

    Omaha, Nebraska, 68198-6846, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Western General Hospital

    RECRUITING

    Edinburgh, EH4 2XU, United Kingdom

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CCS1477 (inobrodib) taken as an oral capsule, sometimes combined with other cancer drugs

What this could lead to

If it works, this could point toward a new treatment option for people with advanced blood cancers that have stopped responding to standard therapies.

What could go wrong

This is an early-phase trial (Phase 1/2a) with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects are possible and being closely monitored.

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia hematopoietic and lymphoid system neoplasm mature T-cell and NK-cell non-Hodgkin lymphoma myelodysplastic syndrome non-Hodgkin lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA HAEMATOLOGICAL MALIGNANCY HAEMATOLOGICAL MALIGNANCY HIGHER-RISK MYELODYSPLASTIC SYNDROME HIGHER-RISK MYELODYSPLASTIC SYNDROME MULTIPLE MYELOMA NON HODGKIN LYMPHOMA NON-HODGKIN LYMPHOMA PERIPHERAL T CELL LYMPHOMA